Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
Chen CY, Chuang WL, Qin A, Zhang WH, Zhu LY, Zhang GQ, Chen JJ, Lo CC, Zhou X, Mao X, Shang J, Kuo HT, Xie W, Chen CH, Lo GH, Jun DW, Dang S, Tsai CY, Wang TF, Lai HH, Tseng KC, Huang YW, Chen PJ. Chen CY, et al. Among authors: shang j. JGH Open. 2022 Oct 10;6(11):782-791. doi: 10.1002/jgh3.12825. eCollection 2022 Nov. JGH Open. 2022. PMID: 36406648 Free PMC article.
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM; YIC Efficacy Trial Study Team. Xu DZ, et al. Among authors: shang j. J Hepatol. 2013 Sep;59(3):450-6. doi: 10.1016/j.jhep.2013.05.003. Epub 2013 May 11. J Hepatol. 2013. PMID: 23669281 Clinical Trial.
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.
Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Rao H, et al. Among authors: shang j. J Gastroenterol Hepatol. 2014 Mar;29(3):545-53. doi: 10.1111/jgh.12398. J Gastroenterol Hepatol. 2014. PMID: 24090188 Free PMC article.
China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B.
Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, Zhang Y, Ren H, Tang H, Ding H, Nan Y, Dou X, Han T, Xu X, Duan Z, Wei L, Hou J, Zhuang H, You H, Jia J; CR-Hepb Study Group, Beijing, China. Shan S, et al. Among authors: shang j. Scand J Public Health. 2020 Mar;48(2):233-239. doi: 10.1177/1403494818772188. Epub 2018 May 1. Scand J Public Health. 2020. PMID: 29716439
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study.
Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W, Ma A, Chen Y, Xu M, Xie W, Cheng J, Xie S, Shang J, Cheng J, Xie Q, Ding H, Zhang X, Bai L, Zhang M, Wang B, Chen S, Ma H, Ou X, Jia J, You H. Wu X, et al. Among authors: shang j. Expert Opin Biol Ther. 2018 Jul;18(sup1):61-69. doi: 10.1080/14712598.2018.1451511. Expert Opin Biol Ther. 2018. PMID: 30063860 Clinical Trial.
[HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, Jiang JN, Xie Q, Dou XG, Sun YT, Li YF, Liu YX, Liu GZ, Ma DW, Chi XL, Tang H, Li XO, Xie Y, Chen XP, Jiang JJ, Zha P, Hou JL, Gao ZL, Fan HM, Ding JG, Zhang DZ, Ren H. Hu P, et al. Among authors: shang j. Zhonghua Gan Zang Bing Za Zhi. 2018 Oct 20;26(10):756-764. doi: 10.3760/cma.j.issn.1007-3418.2018.10.005. Zhonghua Gan Zang Bing Za Zhi. 2018. PMID: 30481882 Clinical Trial. Chinese.
[A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
Gao YH, Li GM, Jin QL, Zhao YR, Jia ZS, Mao XR, Yang YF, Shang J, Wang GC, Xie W, Wu SM, Zhang MX, Hou JL, Li DL, Nan YM, Guan YJ, Zhu CX, Yuan YZ, Wei L. Gao YH, et al. Among authors: shang j. Zhonghua Gan Zang Bing Za Zhi. 2019 May 20;27(5):352-357. doi: 10.3760/cma.j.issn.1007-3418.2019.05.006. Zhonghua Gan Zang Bing Za Zhi. 2019. PMID: 31177659 Clinical Trial. Chinese.
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.
Ji F, Li J, Liu L, Liang J, Wang X, Liu J, Cai D, Huang R, Zhang J, Wang Q, Nan Y, Li J, Ye Q, Zhang M, Xu Q, Guo F, Zhao C, Liu L, He C, Li Y, Wang W, Kam LY, Tran S, Maeda M, Mizuta A, Li Z, Dang S, Ren W, Zhu Q, Cheung R, Niu J, Xie W, Pan H, Ren H, Wu C, Shang J, Wang F, Nguyen MH. Ji F, et al. Among authors: shang j. J Gastroenterol Hepatol. 2021 Mar;36(3):767-774. doi: 10.1111/jgh.15192. Epub 2020 Aug 5. J Gastroenterol Hepatol. 2021. PMID: 32840326
Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial.
Tang J, Gu J, Chu N, Chen Y, Wang Y, Xue D, Xie Q, Li L, Mei Z, Wang X, Li J, Chen J, Li Y, Yang C, Wang Y, Shang J, Xie W, Hu P, Li D, Zhao L, Lan P, Wang C, Chen C, Mao Y. Tang J, et al. Among authors: shang j. Liver Int. 2022 Aug;42(8):1803-1813. doi: 10.1111/liv.15290. Epub 2022 May 25. Liver Int. 2022. PMID: 35567757 Clinical Trial.
2,976 results